Understanding Momentum Shifts in (IRON)
This article analyzes Disc Medicine Inc. (NASDAQ: IRON), indicating weak sentiment across all time horizons supporting a short bias. It details a short setup with a high risk-reward ratio, targeting a 16.7% downside. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Is Disc Medicine (IRON) Cheap On FDA Setback And Legal Investigations?
Disc Medicine (IRON) shares have fallen after the FDA issued a Complete Response Letter for bitopertin, requesting more clinical evidence, and triggering legal investigations into prior disclosures. While the company is considered 21% undervalued based on a narrative fair value of $83, and has a cash runway into 2029, its P/B ratio suggests it might be expensive compared to peers, especially given its cash burn and ongoing regulatory and legal risks. Investors are advised to weigh these factors against potential upsides from other drug candidates.
Bank of America Corp DE Makes New $9.88 Million Investment in Disc Medicine, Inc. $IRON
Bank of America Corp DE has made a new $9.88 million investment in Disc Medicine, Inc. (NASDAQ:IRON), acquiring 135,111 shares and now owning approximately 3.53% of the company. Despite the stock opening down 1.8% and trading below its 12-month high, Disc Medicine reported a smaller-than-expected quarterly loss, and analysts maintain a generally positive outlook with a consensus price target of $110.18. However, company insiders have sold a significant amount of shares recently, totaling about $12.85 million.
Disc Medicine Faces Investor Investigations Over FDA Letter
Disc Medicine (NASDAQ: IRON) is under investigation by multiple securities law firms following the FDA's decline to approve its experimental drug, bitopertin, for erythropoietic protoporphyria in February 2026. The FDA requested additional clinical evidence, leading to a significant drop in Disc Medicine's stock. While law firms are investigating potential misleading disclosures, the company is now focusing on its Phase 3 APOLLO trial, which could provide the necessary evidence for future FDA approval.
Did Early Trial Results Just Shift Disc Medicine (IRON) Stock Narrative?
Disc Medicine (IRON) recently announced positive early Phase 2 trial results for DISC-3405 in polycythemia vera, which showed improved iron regulation and reduced need for phlebotomy. This development strengthens Disc Medicine's investment narrative, focusing on real-world patient outcomes in hematology, alongside its other active program, selcodebart, for myelofibrosis. Despite these clinical successes, the company remains unprofitable and will need to finance its capital-intensive pipeline, making trial progression and funding access critical risk factors.
Behavioral Patterns of IRON and Institutional Flows
This article analyzes the behavioral patterns and institutional flows for Disc Medicine Inc. (NASDAQ: IRON), providing AI-generated trading strategies. It highlights a neutral near-term sentiment with potential for moderate mid-term weakness, identifying resistance tests and a significant risk-reward short setup. The analysis offers specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies across multiple time horizons.
Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Recommendation of "Moderate Buy" from Analysts
Disc Medicine, Inc. (NASDAQ:IRON) has received an average "Moderate Buy" rating from analysts, with eleven out of thirteen recommending the stock as a buy and an average 12-month price target of $110.18. The company recently reported a quarterly loss of $1.54 per share, outperforming analyst expectations. Despite high institutional ownership, company insiders have sold a significant number of shares in the past three months.
Wells Fargo Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $86
Wells Fargo has reiterated its "Buy" rating for Disc Medicine (IRON.US) and increased the price target to $86. This adjustment reflects the firm's continued confidence in the company's prospects.
Disc Medicine (IRON) Reports Encouraging RESTORE PV Data, Is The Stock Undervalued?
Disc Medicine (IRON) recently announced positive Phase 2 RESTORE-PV data for its antibody DISC-3405, showing controlled hematocrit and fewer phlebotomies in polycythemia vera patients. Despite a recent share price dip, a discounted cash flow (DCF) model suggests the stock could be significantly undervalued, with a fair value of $228.43 compared to its current trading price of $68.57. However, price-to-book ratios indicate some optimism is already factored in, and future trial outcomes could impact the valuation.
Disc Medicine CEO Quisel John D Exercises Options, Holding 262,064 Shares Post-Transaction
Disc Medicine CEO Quisel John D exercised options to acquire 36,000 shares at $1.01 each on September 15, 2026. Following this transaction, he now holds a total of 262,064 shares and 150,120 derivative securities. The option exercise increased his total shares by approximately 13.7% and reduced his derivative holdings by about 19.3%.
Disc Medicine (NASDAQ: IRON) CEO turns 36,000 options into stock
Disc Medicine's CEO, John D. Quisel, exercised options for 36,000 shares of common stock on September 15, 2026, at an exercise price of $1.01 per share. This transaction increased his direct common share holdings to 262,064 shares, with an additional 150,120 option shares remaining. The options were fully vested, and no Rule 10b5-1 trading plan was reported.
[Form 4] Disc Medicine, Inc. Insider Trading Activity
A Form 4 filing reveals insider trading activity at Disc Medicine, Inc. (IRON). Director Kevin Bitterman exercised and sold 27,136 shares for an approximate pre-tax spread of $679K. The filing details the transaction, including the exercise of stock options and subsequent sale of common stock, and the resulting holdings after the transaction.
Kevin Bitterman Sells 27,136 Shares of Disc Medicine (NASDAQ:IRON) Stock
Director Kevin Bitterman sold 27,136 shares of Disc Medicine (NASDAQ:IRON) stock for approximately $1.90 million, reducing his stake by 79.18%. Despite this insider selling, Disc Medicine exceeded EPS estimates, and analysts maintain a positive "Moderate Buy" rating with a consensus price target of $109.55. The company's stock experienced a slight dip following the transaction.
Disc Medicine at Morgan Stanley conference: pipeline nears key tests By Investing.com
Disc Medicine presented at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting its pipeline which is nearing crucial clinical and regulatory milestones. The company has sufficient cash reserves to fund operations until 2029 and anticipates significant data readouts and FDA meetings by the end of 2024 and into 2025 for its lead programs in erythropoietic protoporphyria, myelofibrosis-associated anemia, and polycythemia vera. Despite facing competition, Disc Medicine believes its therapies offer distinct advantages and is preparing for commercialization in rare disease and heme-oncology markets.
Squarepoint Ops LLC Increases Stock Position in Disc Medicine, Inc. $IRON
Squarepoint Ops LLC significantly increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 139.3% in the second quarter, now owning 75,872 shares valued at $5.55 million. Despite a recent 5.5% stock drop and insider selling, institutional ownership in Disc Medicine remains high at 83.7%, with analysts generally maintaining a "Moderate Buy" rating and an average price target of $109.55. The company, a clinical-stage biopharmaceutical firm, focuses on developing treatments for serious hematologic diseases and recently beat analyst expectations for its quarterly loss.
Disc Medicine (NASDAQ:IRON) Shares Down 5% - Should You Sell?
Disc Medicine (NASDAQ:IRON) shares dropped 5% to approximately $70.45, with trading volume significantly below average. Despite this, analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of $109.55. The company is currently unprofitable, reporting a quarterly loss of $1.54 per share, and has seen $15.9 million worth of insider stock sales in the past 90 days, while institutional investors hold 83.7% of the stock.
Opaleye Management Inc. Raises Stock Position in Disc Medicine, Inc. $IRON
Opaleye Management Inc. significantly increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 103.1% in the second quarter, now owning 855,000 shares valued at $62.5 million. Despite institutional investors holding a large majority of the stock, company insiders have been net sellers, with CEO John D. Quisel and Director Kevin Bitterman selling shares worth approximately $15.9 million in the last three months. Analysts maintain a "Moderate Buy" consensus with an average price target of $109.55, though the clinical-stage biotech faces inherent development risks.
Disc Medicine reports promising DISC-3405 Phase 2 data
Disc Medicine announced positive initial Phase 2 data for DISC-3405 in polycythemia vera patients, showing control of hematocrit, reduced phlebotomy, and favorable safety. The company also highlighted promising Phase 2 results for selcodebart in anemia of myelofibrosis, advancing both programs towards pivotal development in myeloproliferative neoplasms. An analyst rating indicates a Buy with a $120.00 price target for Disc Medicine (IRON) stock.
Form 8K Disc Medicine Inc For: 10 September By Investing.com
This article reports on the filing of a Form 8K by Disc Medicine Inc. on September 10th. The primary content of the article is the title itself, with the rest of the page dedicated to market data and unrelated news headlines.
Disc Medicine reports positive phase 2 trial results for DISC-3405 By Investing.com
Disc Medicine Inc. (NASDAQ:IRON) announced positive initial results from its RESTORE-PV Phase 2 trial for DISC-3405 in patients with polycythemia vera. The treatment significantly reduced the need for phlebotomy, maintained hematocrit levels, and improved patient symptoms. DISC-3405, an investigational anti-TMPRSS6 monoclonal antibody, was generally well-tolerated and is expected to have further updates by year-end, including data from a Phase 1b trial in sickle cell disease.
Disc Medicine reports positive phase 2 trial results for DISC-3405
Disc Medicine announced positive initial results from its RESTORE-PV Phase 2 trial of DISC-3405 for polycythemia vera. The treatment significantly reduced the need for phlebotomy, maintained hematocrit levels, and improved symptoms in patients, showing a good safety profile. The company plans to provide further updates on this trial and initial data from a Phase 1b trial for sickle cell disease later this year.
Form 8K Disc Medicine Inc For: 10 September By Investing.com
This article announces that Disc Medicine Inc. filed a Form 8K on September 10. The filing is a standard corporate disclosure document often used to report significant events that shareholders should know about. The article itself does not provide details of the 8K content but is a brief notification of its existence.
Disc Medicine's (IRON) "Outperform" Rating Reiterated at Wedbush
Wedbush has reaffirmed its "outperform" rating for Disc Medicine (IRON), setting a $100 price target, which implies a 30.7% upside. The company reported a quarterly EPS of -$1.54, exceeding consensus estimates, and institutional investors hold a significant 83.7% stake. Several other analysts also hold "buy" or "overweight" ratings, contributing to a "Moderate Buy" consensus.
Officer at Disc Medicine (NASDAQ: IRON) plans to sell 27,136 shares
An officer at Disc Medicine (NASDAQ: IRON), Kevin J. Bitterman, has filed a Form 144 indicating an intent to sell up to 27,136 shares of common stock. The aggregate market value of these shares is approximately $1.9 million, and the sale is related to an exercise of options under a registered plan scheduled for September 11, 2026. This potential sale accounts for a small fraction of the 38,392,844 common shares outstanding.
Disc Medicine Reports Positive Initial RESTORE-PV Results for DISC-3405 in Polycythemia Vera
Disc Medicine announced positive initial results from its Phase 2 RESTORE-PV trial for DISC-3405, a monoclonal antibody for polycythemia vera. The trial demonstrated that DISC-3405 effectively increased hepcidin, reduced serum iron, controlled hematocrit, and significantly decreased the need for phlebotomy in patients. These findings suggest DISC-3405 could be a breakthrough treatment, offering improved symptom management and a favorable safety profile for PV patients.
Disc Medicine faces class action over alleged misleading FDA drug approval info causing 22% stock drop.
Disc Medicine, Inc. is facing a class action lawsuit initiated by The Rosen Law Firm after the FDA rejected its new drug application for bitopertin, causing a 22% drop in its stock price on February 13, 2026. The lawsuit alleges misleading information and seeks to recover losses for affected investors. Shareholders who purchased Disc Medicine securities are encouraged to join the class action to seek potential compensation.
Legal & General Group Plc Invests $1.35 Million in Disc Medicine, Inc. $IRON
Legal & General Group Plc has acquired a new position in Disc Medicine, Inc. (NASDAQ:IRON), purchasing 18,458 shares valued at approximately $1.35 million, representing about 0.48% of the company. Other institutional investors have also increased their holdings, with institutional ownership now at 83.70%. The company reported better-than-expected quarterly earnings and analysts generally maintain a "Moderate Buy" rating with an average price target of $107.70, despite some recent insider selling.
Wedbush Raises Price Target on Disc Medicine to $100 From $88, Keeps Outperform Rating
Wedbush has increased its price target for Disc Medicine (IRON) from $88 to $100, while maintaining an Outperform rating on the stock. According to analyst data, Disc Medicine currently has an average rating of "buy" and a mean price target of $101.58.
The Manufacturers Life Insurance Company Takes Position in Disc Medicine, Inc. $IRON
The Manufacturers Life Insurance Company has acquired a new position in Disc Medicine, Inc. (NASDAQ:IRON), purchasing 27,771 shares valued at approximately $2.03 million. Other institutional investors have also adjusted their holdings, with institutional ownership reaching 83.7%. Despite some insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $107.70, and the company recently beat earnings estimates.
Man Group plc Takes $1.09 Million Position in Disc Medicine, Inc. $IRON
Man Group plc has acquired a new stake of $1.09 million in Disc Medicine, Inc. (NASDAQ:IRON), purchasing 14,925 shares. This investment means Man Group plc now owns approximately 0.39% of the company, with institutional investors collectively holding 83.7% of IRON's outstanding shares. Despite positive analyst sentiment with an average price target of $107.70, company insiders have sold approximately $11.4 million in shares over the past 90 days.
Kevin Bitterman Sells 129 Shares of Disc Medicine (NASDAQ:IRON) Stock
Disc Medicine Director Kevin Bitterman sold 129 shares of Disc Medicine (NASDAQ:IRON) stock on September 1st at an average price of $79.95, totaling $10,313.55. This transaction, executed under a Rule 10b5-1 trading plan, leaves him with 14,012 shares. Bitterman also conducted larger sales on September 2nd and 3rd, selling a combined 54,367 shares for approximately $4.36 million.
Kevin Bitterman Sells 5,203 Shares of Disc Medicine (NASDAQ:IRON) Stock
Disc Medicine director Kevin Bitterman sold 5,203 shares of the company's stock for over $416,000 on September 3rd, reducing his holdings by 27.9%. This sale follows previous transactions on September 1st and 2nd. Despite these insider sales, analysts generally maintain a "Moderate Buy" rating for Disc Medicine with an average price target of $107.70, and the company recently beat earnings estimates.
Insider Selling: Disc Medicine (NASDAQ:IRON) Director Sells $3,941,477.88 in Stock
Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman sold 49,164 shares of the company's stock for approximately $3.94 million, reducing his ownership by 78.46%. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $107.70, and institutional investors own a significant portion of the stock.
Bank of New York Mellon Corp Takes Position in Disc Medicine, Inc. $IRON
Bank of New York Mellon Corp has initiated a position in Disc Medicine, Inc. (NASDAQ:IRON), purchasing over 204,000 shares valued at approximately $15 million. This move comes as institutional investors now collectively own 83.7% of Disc Medicine, despite recent insider selling by the COO and CEO. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target significantly above the current stock price.
Cantor Fitzgerald reiterates Disc Medicine stock rating on survey data
Cantor Fitzgerald has reiterated an Overweight rating and a $125 price target for Disc Medicine (NASDAQ:IRON), citing strong commercial adoption potential for selcodebart based on physician surveys. The firm projects peak sales for selcodebart alone could reach $1.93 billion to $2.89 billion, with simulations suggesting an equity valuation of up to $148 per share. This positive outlook follows recent clinical trial data and regulatory alignment for its pipeline therapies.
How (IRON) Movements Inform Risk Allocation Models
This article analyzes Disc Medicine Inc. (NASDAQ: IRON) through AI-driven risk allocation models. It highlights weak near-term sentiment leading to a bearish positioning, with an exceptional 51.7:1 risk-reward short setup targeting 14.8% downside. The analysis provides distinct trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis to inform institutional trading decisions.
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Disc Medicine, Inc. announced it will present data from multiple clinical programs at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. The presentations will include initial data from the RESTORE-PV trial of DISC-3405 in patients with polycythemia vera. The meeting is scheduled to take place in Houston, Texas, from September 9-12, 2026.
Disc Medicine to Present RESTORE-PV and RALLY-MF Data at SOHO Annual Meeting
Disc Medicine, Inc. will present clinical trial data for DISC-3405 and DISC-0974 at the SOHO Annual Meeting from September 9-12, 2026, in Houston, Texas. Key presentations include initial data from the Phase 2 RESTORE-PV trial for polycythemia vera patients, focusing on safety and efficacy, and findings related to anemia treatment in myelofibrosis. The company aims to address unmet medical needs in myeloproliferative neoplasms with these investigational agents.
Disc Medicine, Inc. $IRON Shares Bought by Algert Global LLC
Algert Global LLC significantly increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 128.6% in the second quarter, bringing its total holdings to 51,850 shares valued at approximately $3.79 million. Despite insider selling, institutional investors collectively own 83.7% of the company, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $106.50. The company recently beat quarterly EPS expectations, reporting a loss of $1.54 per share against an estimated loss of $1.71.
Deutsche Bank AG Acquires New Holdings in Disc Medicine, Inc. $IRON
Deutsche Bank AG has acquired a new position in Disc Medicine, Inc. (NASDAQ:IRON), purchasing over 30,000 shares valued at approximately $2.24 million. This move comes as institutional investors now own 83.70% of the company, and analysts maintain a "Moderate Buy" rating with a $106.50 price target. Despite recent insider selling, Disc Medicine reported better-than-expected quarterly earnings.
BlackRock Inc. Makes New Investment in Disc Medicine, Inc. $IRON
BlackRock Inc. has acquired a new stake of 2.47 million shares in Disc Medicine, Inc. (NASDAQ:IRON) worth approximately $180.5 million, giving it a 6.47% ownership. Other institutional investors have also increased their holdings, with institutional ownership now standing at 83.70%. Despite positive analyst sentiment with a "Moderate Buy" rating and an average price target of $106.50, company insiders sold shares valued at $11.4 million in the last quarter.
Disc Medicine faces class action over FDA rejection and stock drop after misleading info claims
Disc Medicine is facing a class action lawsuit following the FDA's rejection of its drug application, which caused a 22% drop in its stock price. The lawsuit alleges that Disc Medicine misled investors, and The Rosen Law Firm is investigating to help shareholders recover losses. Affected investors are encouraged to join the class action without upfront fees.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the U.S. FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock price drop. The firm encourages investors who purchased Disc Medicine securities to join a prospective class action to recover losses. Rosen Law Firm highlights its track record in securities class actions and invites affected investors to contact them for more information.
Will FDA Bitopertin Rejection and New Legal Probe Change Disc Medicine's (IRON) Narrative?
Disc Medicine (IRON) faces new scrutiny after the FDA rejected its bitopertin program and a law firm began investigating potential securities claims. The company's investment narrative now heavily relies on its heme-focused pipeline, particularly upcoming APOLLO Phase 3 results, to justify ongoing losses, while also navigating new legal and disclosure risks. Investors are advised to consider these factors, as the stock may still be trading above its fair value despite recent retreats.
Handelsbanken Fonder AB Buys Shares of 12,700 Disc Medicine, Inc. $IRON
Handelsbanken Fonder AB has acquired 12,700 shares of Disc Medicine, Inc. (NASDAQ:IRON) valued at approximately $929,000, as revealed in its latest SEC filing. This acquisition is part of broader institutional investor activity, with institutional ownership now at 83.70%. Despite some insider selling, analysts maintain a "Moderate Buy" rating for Disc Medicine, with a consensus target price of $106.50, and the company recently reported a narrower-than-expected quarterly loss.
Disc Medicine CEO John Quisel sells $2.6m in shares
Disc Medicine CEO John D. Quisel sold 33,000 shares of the company's common stock for over $2.6 million on August 17, 2026, as part of a pre-arranged trading plan. Concurrently, he exercised options to acquire an equal number of shares. This follows recent positive clinical trial data and regulatory alignment for Disc Medicine's investigational treatments, leading to reiterated "Overweight" and "Buy" ratings from analysts, despite an InvestingPro analysis suggesting the stock is overvalued.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after its stock price fell 22% due to a U.S. Food and Drug Administration Complete Response Letter regarding its bitopertin program. Shareholders who suffered losses are encouraged to contact the firm to potentially join a class action lawsuit. The firm highlights its experience in securities class actions and successful recovery of investor losses.
Insider Selling: Disc Medicine (NASDAQ:IRON) CEO Sells 33,000 Shares of Stock
Disc Medicine (NASDAQ:IRON) CEO John Quisel sold 33,000 shares of company stock for approximately $2.61 million, reducing his direct ownership by 12.74%. Despite this insider selling, the stock rose 0.2% to $80.20, and the company reported a smaller-than-expected quarterly loss. Analysts maintain a "Moderate Buy" consensus with an average target price of $106.50, and institutional investors hold a significant 83.7% of the stock.
Disc Medicine (IRON) CEO sells 33K shares under trading plan
Disc Medicine, Inc. (IRON) CEO John D. Quisel exercised options for 33,000 shares at $13.50 per share and subsequently sold all 33,000 shares in three open-market transactions on August 17, 2026. The sales were executed at weighted average prices between $78.1061 and $79.8420 per share, totaling approximately $2.61 million in gross proceeds. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on March 12, 2026.
Disc Medicine CEO John D. Quisel disposes of USD 2.63 million in common shares
Disc Medicine CEO John D. Quisel exercised options for 33,000 shares on August 17, 2026, at $13.5 per share. The same day, he sold these 33,000 shares for approximately $2.63 million, with weighted-average prices ranging from $78.11 to $79.84. Following these transactions, his direct holdings of common stock decreased to 226,064 shares, and stock options held dropped to 91,586.
